Stockreport

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Title: Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open [Read more]